Enhancing the Patient-Provider Connection: Practical Strategies for Improving Outcomes in Obesity Management Webcast Post-Test

Question Title

* 1. After this session, please rate how your level of confidence changed.

Feel no more confident than before.

Feel a little more confident than before.

Feel somewhat more confident.

Feel more confident than before.

Feel a lot more confident than before.

Question Title

* 2. The CDC contends that in 2017, more than half of the states in the United States had an obesity prevalence rate of ≥30%. In which geographical areas are obesity rates the highest?

North and Northeast

South and Midwest

West and Northwest

Question Title

* 3. William, a 52-year-old non-Hispanic black man with T2DM, is 6’1” and weighs 215 lbs
(BMI 28). His A1c fluctuates between 7% and 8%. Which currently approved anti-obesity medication do guidelines from the Endocrine Society and AACE/ACE recommend for a patient like this?

Liraglutide

Lorcaserin

Naltrexone/bupropion

Phentermine/topiramate

Question Title

* 4. Which of the following is an example of effectively modeling the “Assist” component of
The 5 A’s of Obesity Counseling?

Providing help in accessing providers and arranging follow-up appointments

Discussing weight loss treatment options

Encouraging a small percentage of weight loss at a time rather than large amounts

Conjunctival injection

Question Title

* 5. Comorbidities and other conditions are important considerations when choosing an anti-obesity medication. Which of the drugs approved for obesity management should be used with caution or avoided in patients who are being treated for depression?

Phentermine and phentermine/topiramate

Lorcaserin and naltrexone/bupropion

Liraglutide, lorcaserin, and orlistat